In-vitro effects of the antimicrobial peptide Ala8,13,18-magainin II amide on isolated human first trimester villous trophoblast cells

Table 1 Characteristics of targets and primary antibodies used in the study

Antigen	Specification of antibody	Final concentration	Purpose*
β-actin	Sheep IgG^a	2.0 μg/ml	Internal normalization control, used in WB
Cytokeratin 7	Mouse IgG^b	6 μg/ml	Epithelial cell marker, used in ICC
Cytokeratin 18 neo-epitope (CK18f)	Mouse IgG^c	1:50 (WB); 1:20 (ICC)	Early apoptosis marker, used in WB and ICC
βhCG	Rabbit IgG^c	4 μg/ml (WB); 10 μg/ml (ICC)	CTB differentiation marker, used in WB and ICC
hPL Goat IgG^d		3 μg/ml (WB); 7 μg/ml (ICC)	CTB differentiation marker, used in WB and ICC
Vimentin	Mouse IgG^a	3 μg/ml	Cytoskeletal protein marker for fibroblasts, used in ICC
Vitronectin receptor, Integrin αVβ3 (CD51)	Mouse IgG^e	10 μg/ml	Invasive CTB marker, used in ICC
von Willebrand factor	Rabbit IgG^c	25 μg/ml	Endothelial cell marker (in Weibel-Palade bodies), used in ICC

*see references [17–19, 23–27, 32] for details.
CTB, cytotrophoblast cells. ICC, immunocytochemistry. WB, Western blot analysis.
^aR&D Systems, Minneapolis. ^bSigma Chemical, St Louis, MO, USA. ^cDako, Glostrup, Denmark. ^dSanta Cruz Biotechnology, Santa Cruz, CA, USA. ^eZymed Laboratories, San Francisco, CA, USA.

ISSN: 1477-7827